Fig. 5

Development of humoral [anti-S-RBD-IgGs (A); Nabs (B)] and cellular [SARS-CoV-2 S, N antigens specific T cell clones, (C)] adaptive immune responses five months (M5) post-vaccination with the first dose of BNT162b2. qRT-PCR SARS-CoV-2 positive (along with the duration in months post-qRT-PCR testing) vaccinated donors are indicated. A non-vaccinated COVID-19 recovered donor (COV-19; female, age 28 years old) and two non-vaccinated COVID-19 negative participants (NEG-1, NEG-2; females, ages 28 and 32 years old) were also included in these analyses. Stars indicate donors negative for T cell clones specific for the SARS-CoV-2 N protein (including 4 out of 6 participants tested positive with qRT-PCR for SARS-CoV-2 infection) used for coefficient correlation analyses of T cell clones number with anti-S-RBD IgGs or NAbs titers. Values in parenthesis above > 2500 U/mL in (A) denote actual values in U/mL. S protein specific T cell clones/anti-S-RBD IgGs, R (Corr.) 0.180, non-significant; S protein specific T cell clones/NAbs, R (Corr.) 0.492, P < 0.05; anti-S-RBD IgGs/NAbs, R (Corr.) 0.432, P < 0.05. Kinetics (median with 95% CI) of humoral responses (NAbs) at shown vaccinated recipients (n = 21) from D1 to M5 are reported in Additional file 1: Fig. S7